|
1.
|
Eramo A, Ricci-Vitiani L, Zeuner A, et al:
Chemotherapy resistance of glioblastoma stem cells. Cell Death
Differ. 13:1238–1241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Phillips TM, McBride WH and Pajonk F: The
response of CD24(−/low)/CD44+ breast cancer-initiating cells to
radiation. J Natl Cancer Inst. 98:1777–1785. 2006.
|
|
3.
|
Tanei T, Morimoto K, Shimazu K, et al:
Association of breast cancer stem cells identified by aldehyde
dehydrogenase 1 expression with resistance to sequential paclitaxel
and epirubicin-based chemotherapy for breast cancers. Clin Cancer
Res. 15:4234–4241. 2009. View Article : Google Scholar
|
|
4.
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar
|
|
5.
|
Mimeault M, Hauke R, Mehta PP and Batra
SK: Recent advances in cancer stem/progenitor cell research:
therapeutic implications for overcoming resistance to the most
aggressive cancers. J Cell Mol Med. 11:981–1011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Reguart N, He B, Taron M, You L, Jablons
DM and Rosell R: The role of Wnt signaling in cancer and stem
cells. Future Oncol. 1:787–797. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Mishra L, Shetty K, Tang Y, Stuart A and
Byers SW: The role of TGF-beta and Wnt signaling in
gastrointestinal stem cells and cancer. Oncogene. 24:5775–5789.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
He B, Barg RN, You L, et al: Wnt signaling
in stem cells and non-small-cell lung cancer. Clin Lung Cancer.
7:54–60. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Kruger JA, Kaplan CD, Luo Y, et al:
Characterization of stem cell-like cancer cells in immune-competent
mice. Blood. 108:3906–3912. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Scholer HR, Dressler GR, Balling R,
Rohdewohld H and Gruss P: Oct-4: a germline-specific transcription
factor mapping to the mouse t-complex. EMBO J. 9:2185–2195.
1990.PubMed/NCBI
|
|
11.
|
Scholer HR, Ruppert S, Suzuki N, Chowdhury
K and Gruss P: New type of POU domain in germ line-specific protein
Oct-4. Nature. 344:435–439. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Odorico JS, Kaufman DS and Thomson JA:
Multilineage differentiation from human embryonic stem cell lines.
Stem Cells. 19:193–204. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Hubner K, Fuhrmann G, Christenson LK, et
al: Derivation of oocytes from mouse embryonic stem cells. Science.
300:1251–1256. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Chew JL, Loh YH, Zhang W, et al:
Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the
Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol.
25:6031–6046. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Park IH, Zhao R, West JA, et al:
Reprogramming of human somatic cells to pluripotency with defined
factors. Nature. 451:141–146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Maruyama M, Ichisaka T, Nakagawa M and
Yamanaka S: Differential roles for Sox15 and Sox2 in
transcriptional control in mouse embryonic stem cells. J Biol Chem.
280:24371–24379. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Masui S, Nakatake Y, Toyooka Y, et al:
Pluripotency governed by Sox2 via regulation of Oct3/4 expression
in mouse embryonic stem cells. Nat Cell Biol. 9:625–635. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ginis I, Luo Y, Miura T, et al:
Differences between human and mouse embryonic stem cells. Dev Biol.
269:360–380. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ponti D, Costa A, Zaffaroni N, et al:
Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res.
65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Balic M, Lin H, Young L, et al: Most early
disseminated cancer cells detected in bone marrow of breast cancer
patients have a putative breast cancer stem cell phenotype. Clin
Cancer Res. 12:5615–5621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Mylona E, Giannopoulou I, Fasomytakis E,
et al: The clinicopathologic and prognostic significance of
CD44+/CD24(-/low) and CD44−/CD24+
tumor cells in invasive breast carcinomas. Hum Pathol.
39:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Wright MH, Calcagno AM, Salcido CD,
Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors
contain distinct CD44+/CD24− and
CD133+ cells with cancer stem cell characteristics.
Breast Cancer Res. 10:R102008. View
Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Stride BD, Valdimarsson G, Gerlach JH,
Wilson GM, Cole SP and Deeley RG: Structure and expression of the
messenger RNA encoding the murine multidrug resistance protein, an
ATP-binding cassette transporter. Mol Pharmacol. 49:962–971.
1996.PubMed/NCBI
|
|
25.
|
D’Hondt V, Caruso M and Bank A:
Retrovirus-mediated gene transfer of the multidrug
resistance-associated protein (MRP) cDNA protects cells from
chemotherapeutic agents. Hum Gene Ther. 8:1745–1751.
1997.PubMed/NCBI
|
|
26.
|
Lautier D, Canitrot Y, Deeley RG and Cole
SP: Multidrug resistance mediated by the multidrug resistance
protein (MRP) gene. Biochem Pharmacol. 52:967–977. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Abaan OD, Mutlu PK, Baran Y, Atalay C and
Gunduz U: Multidrug resistance mediated by MRP1 gene overexpression
in breast cancer patients. Cancer Invest. 27:201–205. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Chuthapisith S, Eremin J, El-Sheemey M and
Eremin O: Breast cancer chemoresistance: emerging importance of
cancer stem cells. Surg Oncol. 19:27–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Dave B and Chang J: Treatment resistance
in stem cells and breast cancer. J Mammary Gland Biol Neoplasia.
14:79–82. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Allikmets R, Schriml LM, Hutchinson A,
Romano-Spica V and Dean M: A human placenta-specific ATP-binding
cassette gene (ABCP) on chromosome 4q22 that is involved in
multidrug resistance. Cancer Res. 58:5337–5339. 1998.PubMed/NCBI
|
|
32.
|
Doyle LA, Yang W, Abruzzo LV, et al: A
multidrug resistance transporter from human MCF-7 breast cancer
cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ross DD, Yang W, Abruzzo LV, et al:
Atypical multidrug resistance: breast cancer resistance protein
messenger RNA expression in mitoxantrone-selected cell lines. J
Natl Cancer Inst. 91:429–433. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Liu G, Yuan X, Zeng Z, et al: Analysis of
gene expression and chemoresistance of CD133+ cancer
stem cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Khan S, Aspe JR, Asumen MG, et al:
Extracellular, cell-permeable survivin inhibits apoptosis while
promoting proliferative and metastatic potential. Br J Cancer.
100:1073–1086. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Tamm I, Wang Y, Sausville E, et al:
IAP-family protein survivin inhibits caspase activity and apoptosis
induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer
Res. 58:5315–5320. 1998.PubMed/NCBI
|
|
37.
|
Wang J, Guo LP, Chen LZ, Zeng YX and Lu
SH: Identification of cancer stem cell-like side population cells
in human nasopharyngeal carcinoma cell line. Cancer Res.
67:3716–3724. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Kornblau SM, Qiu YH, Bekele BN, et al:
Studying the right cell in acute myelogenous leukemia: dynamic
changes of apoptosis and signal transduction pathway protein
expression in chemotherapy resistant ex-vivo selected ‘survivor
cells’. Cell Cycle. 5:2769–2777. 2006.PubMed/NCBI
|
